OIS Index Nov. 2019

The OIS Index of ophthalmic stocks gained 5.2% in October, posting its first month of positive performance since June. The index lagged the biotech sector (+7.7%) and outperformed an index of medical device stocks (+0.8%) and the broader US stock market (+2.0%).

The largest positive contributor was STAAR Surgical (+27.2%), driven by strong Q3 results. IVERIC bio tripled in value on positive Phase 2b data for Zimura in geographic atrophy secondary to dry age-related macular degeneratio. Clearside Biomedical doubled on an announced license agreement with Bausch Health. Other big movers included Adverum (+33.4%), EyePoint (+24.9%), and Apellis (+22.0%).

For more, visit https://ois.net/ois-index/

About Michael Lachman

Michael Lachman is President of EyeQ Research, which provides market research, analytics, and strategic advisory to ophthalmic companies and investors. Previously, he was a healthcare investment research analyst with Hambrecht & Quist, ThinkEquity Partners, and SAC Capital, and worked in business development, marketing, and R&D for Johnson & Johnson and Baxter.